Cited by 132Gastrointestinal motility and disordersInfant Health and DevelopmentGastroesophageal reflux and treatments

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Alosetron, a 5‐HT 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

Open access

Houghton, Foster, Whorwell·2000·Alimentary Pharmacology & Therapeutics

DOI 10.1046/j.1365-2036.2000.00762.x

Open this paper in CoChat — free account Open PDF

Abstract

Background: Alosetron is a potent and selective 5‐HT 3 receptor antagonist, which has been shown to be beneficial in the treatment of female patients with non‐constipated irritable bowel syndrome. Aims: To investigate the effect of alosetron on whole gut, small bowel and colonic transit in patients with irritable bowel syndrome (Study 1) and healthy volunteers (Study 2). Subjects: Thirteen patients with irritable bowel syndrome and 12 healthy volunteers. Methods: Both studies were randomized, double‐blind, placebo‐controlled with a two‐way crossover design, in which each subject received alosetron (2 mg b.d. administered orally) or placebo for 8 days. Mean whole gut transit was determined from the excretion of radio‐opaque markers; small bowel transit was determined from rise in breath hydrogen after a meal; and colonic transit and segmental transit were evaluated from abdominal X‐ray. In addition, colonic transit was calculated by subtracting small bowel transit time from whole gut transit time. Results: Alosetron increased colonic transit time by prolonging left colonic transit in both patients with irritable bowel syndrome and controls. This resulted in a tendency for the whole gut transit to be delayed in irritable bowel syndrome patients ( P =0.128), which was confirmed in controls ( P =0.047). Conclusion: Alosetron delays colonic transit by prolonging left colonic transit. These results add to the body of evidence suggesting that alosetron should have a therapeutic role in patients with non‐constipated irritable bowel syndrome.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1046/j.1365-2036.2000.00762.x

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

U. S. Householder survey of functional gastrointestinal disorders: Prevalence, sociodemography, and health impact
Drossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
Simplified assessment of segmental colonic transit
Metcalf, A. M., Phillips, S. F., Zinsmeister, A. R., MacCarty, R. L., Beart, R. W., & Wolff, B. G. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90837-7 · Cited by 928
15 Design and Analysis of Cross-Over Trials
Kenward, M. G., & Jones, B. C. (2007) · Handbook of statistics · doi:10.1016/s0169-7161(07)27015-4 · Cited by 873
A new method for studying gut transit times using radioopaque markers
Hinton, J., Lennard‐Jones, J. E., & Young, A. C. (1969) · Gut · doi:10.1136/gut.10.10.842 · Cited by 838
Bowel Patterns Among Subjects Not Seeking g Health Care
Drossman, D. A., Sandler, R. S., McKee, D. C., & Lovitz, A. J. (1982) · Gastroenterology · doi:10.1016/s0016-5085(82)80186-8 · Cited by 711
Design and Analysis of Cross-Over Trials
Jones, B. C., & Kenward, M. G. (1989) · Chapman & Hall/CRC eBooks · doi:10.4324/9780203009277 · Cited by 694
Production and Excretion of Hydrogen Gas in Man
Levitt, M. D. (1969) · New England Journal of Medicine · doi:10.1056/nejm196907172810303 · Cited by 586
328. Note: The Use of None-Parametric Methods in the Statistical Analysis of the Two-Period Change-Over Design
Koch, G. G. (1972) · Biometrics · doi:10.2307/2556170 · Cited by 465
Symptoms of irritable bowel syndrome in a British urban community: Consulters and nonconsulters
Heaton, K. W., O'Donnell, L. J. D., Braddon, F., Mountford, R. A., Hughes, A., & Cripps, P. J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90320-x · Cited by 382
Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns.
Cann, P. A., Read, N. W., Brown, C., Hobson, N., & Holdsworth, C. D. (1983) · Gut · doi:10.1136/gut.24.5.405 · Cited by 365

Show all 34 references

Research works printed but not linked: 3

MayerEA MunakataJ MertzH LemboT BernsteinCN.Visceral hyperalgesia and irritable bowel syndrome. In: Gebhert GF ed. Visceral Pain Progress in Pain Research and Management Vol 5. Seattle USA: IASP Press 1995: 429–68.
Thompson WG, 1992, Functional bowel disease and functional abdominal pain. Working team report, Gastroenterol Int, 5, 75
Lubke HJ, 1988, 5‐HT3 receptors have minimal effects on normal gut function, Gastroenterology, 94, A271

Sorted by citations

Guidelines on the irritable bowel syndrome: mechanisms and practical management
Spiller, R., Aziz, Q., Creed, F., Emmanuel, A., Houghton, L., Hungin, P., Jones, R., Kumar, D., Rubin, G., Trudgill, N., et al. (2007) · Gut · doi:10.1136/gut.2007.119446 · Cited by 818
Irritable bowel syndrome
Ford, A. C., Sperber, A. D., Corsetti, M., & Camilleri, M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31548-8 · Cited by 818
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
Ford, A. C., Moayyedi, P., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., Soffer, E., Spiegel, B. M. R., & Quigley, E. M. M. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.187 · Cited by 664
British Society of Gastroenterology guidelines on the management of irritable bowel syndrome
Vasant, D. H., Paine, P. A., Black, C. J., Houghton, L. A., Everitt, H. A., Corsetti, M., Agrawal, A., Aziz, I., Farmer, A. D., Eugenicos, M. P., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324598 · Cited by 592
Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine
Saha, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i22.6759 · Cited by 500
Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome
Dunlop, S. P., Coleman, N. S., Blackshaw, E., Perkins, A. C., Singh, G., Marsden, C. A., & Spiller, R. E. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00726-8 · Cited by 355
A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Camilleri, M., Chey, W. Y., Mayer, E. A., Northcutt, A. R., Heath, A. T., Dukes, G. E., McSorley, D., & Mangel, A. W. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.14.1733 · Cited by 302
Role of serotonin in the pathophysiology of the irritable bowel syndrome
Crowell, M. D. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705762 · Cited by 289
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function
Barnes, N. M., Ahern, G. P., Bécamel, C., Bockaert, J., Camilleri, M., Chaumont‐Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C. F., Gershon, M. D., et al. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 274
Serotonin and GI clinical disorders
Spiller, R. E. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.07.016 · Cited by 240
An Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225
Meta‐analysis: the treatment of irritable bowel syndrome
Pantoflickova, D., Michetti, P., Fried, M., Beglinger, C., & Blum, A. L. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02267.x · Cited by 223
Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials
Cremonini, F., Delgado‐Aros, S., & Camilleri, M. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00389.x · Cited by 219
Effects of 5-Hydroxytryptamine (Serotonin) Type 3 Antagonists on Symptom Relief and Constipation in Nonconstipated Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Andresen, V., Montori, V. M., Keller, J., West, C. P., Layer, P., & Camilleri, M. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.12.015 · Cited by 212
Efficacy of pharmacological therapies in patients with IBS with diarrhoea or mixed stool pattern: systematic review and network meta-analysis
Black, C. J., Burr, N. E., Camilleri, M., Earnest, D. L., Quigley, E. M., Moayyedi, P., Houghton, L. A., & Ford, A. C. (2020) · Gut · doi:10.1136/gutjnl-2018-318160 · Cited by 191
Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome
Lembo, T., Wright, R. A., Bagby, B., Decker, C., Gordon, S., Jhingran, P. M., & Carter, E. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04128.x · Cited by 191
Crosstalk at the mucosal border: importance of the gut microenvironment in IBS
Öhman, L., Törnblom, H., & Simrén, M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2014.200 · Cited by 185
Serotoninergic neuroenteric modulators
Talley, N. J. (2001) · The Lancet · doi:10.1016/s0140-6736(01)07103-3 · Cited by 177
Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective
Tack, J. F., Fried, M., Houghton, L. A., SPICAK, J., & FISHER, G. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02938.x · Cited by 169
Functional GI disorders: from animal models to drug development
Mayer, E. A., Bradesi, S., Chang, L., Spiegel, B. M. R., Bueller, J. A., & Naliboff, B. D. (2007) · Gut · doi:10.1136/gut.2006.101675 · Cited by 165
Irritable Bowel Syndrome
Ponti, F. D., & Tonini, M. (2001) · Drugs · doi:10.2165/00003495-200161030-00001 · Cited by 147
Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome
Stasi, C., Bellini, M., Bassotti, G., Blandizzi, C., & Milani, S. (2014) · Techniques in Coloproctology · doi:10.1007/s10151-013-1106-8 · Cited by 139
A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS
Chang, L., Ameen, V. Z., Dukes, G. E., McSorley, D., Carter, E. G., & Mayer, E. A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40365.x · Cited by 139
Review article: modulation of the brain–gut axis as a therapeutic approach in gastrointestinal disease
Mayer, E. A., Tillisch, K., & Bradesi, S. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03078.x · Cited by 139
Ligand‐gated ion channels in the enteric nervous system
Galligan, J. J. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00363.x · Cited by 132
Rome III Functional Constipation and Irritable Bowel Syndrome With Constipation Are Similar Disorders Within a Spectrum of Sensitization, Regulated by Serotonin
Shekhar, C., Monaghan, P. J., Morris, J., Issa, B., Whorwell, P. J., Keevil, B. G., & Houghton, L. A. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.014 · Cited by 2,891
Serotonin pharmacology in the gastrointestinal tract: a review
Beattie, D. T., & Smith, J. A. M. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0276-9 · Cited by 121
Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome
Viramontes, B. E., Camilleri, M., McKinzie, S., Pardi, D. S., Burton, D. D., & Thomforde, G. M. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.04138.x · Cited by 119
Mechanosensory Signaling in Enterochromaffin Cells and 5-HT Release: Potential Implications for Gut Inflammation
Liñán-Rico, A., Ochoa‐Cortés, F., Beyder, A., Soghomonyan, S., Zuleta-Alarcón, A., Coppola, V., & Christofi, F. L. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00564 · Cited by 116
Second Asian Consensus on Irritable Bowel Syndrome
Gwee, K., Gonlachanvit, S., Ghoshal, U. C., Chua, A. S. B., Miwa, H., Wu, J. C. Y., Bak, Y., Lee, O. Y., Lu, C., Park, H., et al. (2019) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm19041 · Cited by 112
A dose‐ranging, placebo‐controlled, randomized trial of alosetron in patients with functional dyspepsia
Talley, N. J., ZANTEN, S. V. V., Saez, L. R., Dukes, G. E., Perschy, T. L., Heath, M., Kleoudis, C. S., & Mangel, A. W. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00941.x · Cited by 110
Abnormalities of Serotonin Metabolism and Their Relation to Symptoms in Untreated Celiac Disease
Coleman, N. S., Foley, S., Dunlop, S. P., Wheatcroft, J., Blackshaw, E., Perkins, A. C., Singh, G., Marsden, C. A., Holmes, G. K. T., & Spiller, R. E. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.04.017 · Cited by 106
The Multifaceted Role of Serotonin in Intestinal Homeostasis
Koopman, N., Katsavelis, D., ten Hove, A. S., Brul, S., de Jonge, W. J., & Seppen, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179487 · Cited by 112
Serotonergic modulation of visceral sensation: lower gut
Camilleri, M. (2002) · Gut · doi:10.1136/gut.51.suppl_1.i81 · Cited by 90
Pharmacologic and Complementary and Alternative Medicine Therapies for Irritable Bowel Syndrome
Chey, W. D., Maneerattaporn, M., & Saad, R. (2011) · Gut and Liver · doi:10.5009/gnl.2011.5.3.253 · Cited by 89
Pharmacologic therapy for the irritable bowel syndrome
Talley, N. J. (2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.07306.x · Cited by 89
Alosetron Improves Quality of Life in Women With Diarrhea-Predominant Irritable Bowel Syndrome
Watson, M. E., Lacey, L., Kong, S., Northcutt, A. R., McSorley, D., Hahn, B., & Mangel, A. W. (2001) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03525.x · Cited by 88
Ischemic Colitis and Complications of Constipation Associated With the Use of Alosetron Under a Risk Management Plan: Clinical Characteristics, Outcomes, and Incidences
Chang, L., Tong, K., & Ameen, V. Z. (2010) · The American Journal of Gastroenterology · doi:10.1038/ajg.2010.25 · Cited by 83
Sequelae of Traveler's Diarrhea: Focus on Postinfectious Irritable Bowel Syndrome
Connor, B. A. (2005) · Clinical Infectious Diseases · doi:10.1086/432956 · Cited by 76
Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles
Camilleri, M., & Chang, L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.005 · Cited by 74
Alosetron and irritable bowel syndrome
Mayer, E. A., & Bradesi, S. (2003) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.4.11.2089 · Cited by 73
Disease burden of post-infectious irritable bowel syndrome in The Netherlands
HAAGSMA, J. A., SIERSEMA, P. D., DE WIT, N. J., & HAVELAAR, A. H. (2010) · Epidemiology and Infection · doi:10.1017/s0950268810000531 · Cited by 85
Review: The treatment of irritable bowel syndrome
Lacy, B. E., Weiser, K., & Lee, R. D. (2009) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09104794 · Cited by 66
Updates on treatment of irritable bowel syndrome
Hammerle, C. W., & Surawicz, C. M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2639 · Cited by 65
Serotonergic modulating drugs for functional gastrointestinal diseases
Spiller, R. E. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01612.x · Cited by 60
Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro
Bush, T. G., Spencer, N. J., Watters, N., Sanders, K. M., & Smith, T. K. (2001) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2001.281.4.g974 · Cited by 60
Rationale for using serotonergic agents to treat irritable bowel syndrome
Baker, D. E. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.7.700 · Cited by 59
Mechanosensing Piezo channels in gastrointestinal disorders
Swain, S. M., & Liddle, R. A. (2023) · Journal of Clinical Investigation · doi:10.1172/jci171955 · Cited by 53
Serotonin receptor modulators in the treatment of irritable bowel syndrome
Lackner, J. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s140 · Cited by 47
Sigmoid‐colonic motility in health and irritable bowel syndrome: a role for 5‐hydroxytryptamine
Houghton, L. A., Atkinson, W., Lockhart, S., Fell, C., Whorwell, P. J., & Keevil, B. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00943.x · Cited by 46
Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
“5-HT3 receptors play an important role in visceral pain, and 5-HT3 receptor antagonists decrease painful sensations from the gut and slow intestinal transit.(65,66) 5-HT3 receptor antagonists reportedly slow colonic transit, blunt the gastrocolonic reflex, and reduce rectal sensitivity and postprandial motility,(66,67…”
Background
The role of experimental models in developing new treatments for irritable bowel syndrome
Holschneider, D. P., Bradesi, S., & Mayer, E. A. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.88 · Cited by 40
Review article: current and future treatment approaches for pain in IBS
Paine, P. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16550 · Cited by 42
5-Hydroxytryptophan activates colonic myenteric neurons and propulsive motor function through 5-HT4receptors in conscious mice
Wang, L., Martı́nez, V., Kimura, H., & Taché, Y. (2006) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00289.2006 · Cited by 39
Review article: an analysis of safety profiles of treatments for diarrhoea‐predominant irritable bowel syndrome
Lacy, B. (2018) · Alimentary Pharmacology and Therapeutics · doi:10.1111/apt.14948 · Cited by 36
Selected Interventions in Nuclear Medicine: Gastrointestinal Motor Functions
Odunsi, S. T., & Camilleri, M. (2009) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.11.002 · Cited by 37
Function and Regulation of Colonic Contractions in Health and Disease
Sarna, S. K., & Shi, X.-Z. P. (2006) · Elsevier eBooks · doi:10.1016/b978-012088394-3/50042-8 · Cited by 36
Irritable bowel syndrome: Is it “irritable brain” or “irritable bowel”?
Padhy, S. K., Sahoo, S., Mahajan, S., & Sinha, S. K. (2015) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.169802 · Cited by 38
Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome
Delvaux, M. M. (2004) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.06.004 · Cited by 34
Reassessing the Benefits and Risks of Alosetron
Andresen, V., & Hollerbach, S. H. (2004) · Drug Safety · doi:10.2165/00002018-200427050-00001 · Cited by 34
Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies
Johanson, J. F. (2004) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2004.00550.x · Cited by 31
Effect of bowel cleansing on colonic transit in constipation due to slow transit or evacuation disorder
Sloots, C. E. J., & Felt-Bersma, R. J. F. (2002) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2002.00304.x · Cited by 31
Alosetron in Irritable Bowel Syndrome
Lembo, A. J., Weber, H. C., & Farraye, F. A. (2003) · Drugs · doi:10.2165/00003495-200363180-00002 · Cited by 30
Lipid‐induced colonic hypersensitivity in irritable bowel syndrome: the role of 5‐HT3 receptors
Simrén, M., Simms, L., D'Souza, D. L., Abrahamsson, H., & Björnsson, E. S. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01399.x · Cited by 28
Irritable Bowel Syndrome
Videlock, E. J., & Chang, L. (2016) · Wiley eBooks · doi:10.1002/9781119127437.ch65 · Cited by 32
Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective
Lewis, J. H. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.72 · Cited by 27
Expression and clinical significance of 5‑HT and 5‑HT3R in the intestinal mucosa of patient with diarrhea‑type irritable bowel syndrome
Fu, R., Chen, M., Chen, Y., Mao, G., & Liu, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7297 · Cited by 27
Irritable bowel syndrome: an update on therapeutic modalities
Farhadi, A., Bruninga, K., Fields, J. Z., & Keshavarzian, A. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1211 · Cited by 27
Guidelines for the Treatment of Irritable Bowel Syndrome
Kwon, J. G., Park, K. S., Park, J. H., Park, J. M., Park, C. H., Lee, K. J., Park, H., Rhee, P., & The Korean Society of Neurogastroenterology and Motility (2011) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2011.57.2.82 · Cited by 26
Potential biomarkers.
Spiller, R. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.01.001 · Cited by 62
Current and Emerging Pharmacotherapeutic Options for Irritable Bowel Syndrome
Barboza, J., Talley, N. J., & Moshiree, B. (2014) · Drugs · doi:10.1007/s40265-014-0292-7 · Cited by 24
Advances in the management of irritable bowel syndrome
Cash, B. D., & Chey, W. D. (2003) · Current Gastroenterology Reports · doi:10.1007/s11894-003-0035-5 · Cited by 24
Ileostomy diarrhea
Dupont, A. W., & Sellin, J. H. (2006) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-006-0022-7 · Cited by 24
The quest for biomarkers in IBS—where should it lead us?
Corsetti, M., Oudenhove, L. V., & Tack, J. (2014) · Neurogastroenterology and Motility · doi:10.1111/nmo.12475 · Cited by 26
Treatment of irritable bowel syndrome: sex and gender specific aspects.
Voss, U., Lewerenz, A., & Nieber, K. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-30726-3_21 · Cited by 23
New Treatments for Irritable Bowel Syndrome in Women
Adeyemo, M. A., & Chang, L. (2008) · Women s Health · doi:10.2217/17455057.4.6.605 · Cited by 25
Effect of alosetron on left colonic motility in non‐constipated patients with irritable bowel syndrome and healthy volunteers
Clemens, C. H. M., Samsom, M., Henegouwen, G. P. V. B., Fabri, M., & Smout, A. J. P. M. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01252.x · Cited by 22
Irritable bowel syndrome: a review article.
Vahedi, H., Ansari, R., Mir-Nasseri, M., & Jafari, E. (2010) · Europe PMC (PubMed Central) · Cited by 20
Current gut-directed therapies for irritable bowel syndrome
Chang, H. Y., Kelly, E. C., & Lembo, A. J. (2006) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-006-0013-8 · Cited by 19
Effects of the 5‐HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double‐blind crossover trial
Stacher, G., Weber, U., Stacher-Janotta, G., Bauer, P., Huber, K., Holzäpfel, A., Krause, G., & Steinborn, C. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00180.x · Cited by 19
Management of irritable bowel syndrome
Silk, D. B. A. (2003) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-200306000-00016 · Cited by 18
Inter‐digestive and post‐prandial antro‐pyloro‐duodenal motor activity in humans: effect of 5‐hydroxytryptamine 1 receptor agonism
Calvert, E., Whorwell, P. J., & Houghton, L. A. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.01901.x · Cited by 18
Effects of serotonin 5-HT3 receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats
Hirata, T., Keto, Y., Nakata, M., Takeuchi, A., Funatsu, T., Akuzawa, S., Sasamata, M., & Miyata, K. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.040 · Cited by 16
From psychology to physicality: how nerve growth factor transduces early life stress into gastrointestinal motility disorders later in life
Chow, C. F. W., Che, S., Qin, H., Kwan, H. Y., Bian, Z., & Wong, H. L. X. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1637203 · Cited by 14
Novel Therapies in IBS-D Treatment
Nee, J. W., Zakari, M., & Lembo, A. J. (2015) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-015-0068-5 · Cited by 15
Targeted therapies for diarrhea-predominant irritable bowel syndrome
Olden, K. W. (2012) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s29023 · Cited by 15
Peripherally acting therapies for the treatment of irritable bowel syndrome.
Saad, R. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.12.008 · Cited by 14
Emerging drugs for irritable bowel syndrome
Bradesi, S., Tillisch, K., & Mayer, E. A. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.2.293 · Cited by 14
Small-bowel motility
Aros, S. D., & Camilleri, M. (2001) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200103000-00007 · Cited by 14
Infantile Colic and the Subsequent Development of the Irritable Bowel Syndrome
Kim, J. H., Lee, S. W., Kwon, Y., Ha, E. K., An, J., Cha, H. R., Jeong, S. J., & Han, M. Y. (2022) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm21181 · Cited by 15
Infection as a cause of irritable bowel syndrome
Spiller, R. E. (2003) · Hospital Medicine · doi:10.12968/hosp.2003.64.5.1758 · Cited by 13
Current and Future Therapeutic Options for Irritable Bowel Syndrome with Diarrhea and Functional Diarrhea
Ramos, G. P., & Camilleri, M. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07700-8 · Cited by 14
Activation of KCNQ (KV7) K+ channels in enteric neurons inhibits epithelial Cl− secretion in mouse distal colon
Nickerson, A. J., Rottgen, T. S., & Rajendran, V. M. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00536.2020 · Cited by 12
An overview of 5-HT 3 receptor antagonists as a treatment option for irritable bowel syndrome with diarrhea
Merecz, K., Hirsa, M., Biniszewska, O., Fichna, J., & Tarasiuk, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2214314 · Cited by 11
Effect of alosetron on theophylline pharmacokinetics
Koch, K. M., Ricci, B., Hedayetullah, N., Jewell, D., & Kersey, K. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01477.x · Cited by 11
Irritable bowel syndrome
Sach, J., & Chang, L. (2002) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-002-0049-3 · Cited by 11
Comparative effectiveness of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: a network meta-analysis of randomized controlled studies
Rokkas, T. (2021) · Annals of Gastroenterology · doi:10.20524/aog.2021.0619 · Cited by 10
Colonic Motor and Sensory Function and Dysfunction
Cook, I. J., Brookes, S. J., & Dinning, P. G. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00098-6 · Cited by 10
Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome
Lea, R., & Whorwell, P. J. (2004) · Drug Safety · doi:10.2165/00002018-200427040-00002 · Cited by 9
An Initial Attack of Urinary Stone Disease Is Associated with an Increased Risk of Developing New-Onset Irritable Bowel Syndrome: Nationwide Population-Based Study
Lei, W.-Y., Chang, C.-Y., Wu, J.-H., Lin, F.-H., Chen, C. H., Chang, C.-F., Lin, Y., & Wu, H. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157701 · Cited by 8

Authors: Houghton, Foster, & Whorwell
Affiliations: Manchester University NHS Foundation Trust (GB)
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2000-06
Volume: 14
Issue: 6
Pages: 775-782
ISSN: 0269-2813 (ISSN-L)
1365-2036
DOI: 10.1046/j.1365-2036.2000.00762.x
OpenAlex: W2049197933
Cited by: 132
References: 34
Citations by year: 2026: 2 · 2025: 2 · 2024: 1 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 2 · 2019: 5 · 2018: 3 · 2016: 4 · 2015: 3 · 2014: 8 · 2013: 2 · 2012: 3
FWCI: 10.66
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 571 d)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Research Explorer (The University of Manchester) (publishedVersion)
White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Infant Health and Development
Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Keywords: alosetron, 5-HT3 receptor antagonists, irritable bowel syndrome, colonic transit, whole gut transit, small intestinal transit, radio-opaque markers, breath hydrogen, abdominal radiography
MeSH terms: Adult, Carbolines, Colon, Colonic Diseases, Functional, Double-Blind Method, Female, Gastrointestinal Transit, Humans, Intestine, Small, Male, Middle Aged, Serotonin Antagonists, Cross-Over Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alosetron, a 5‐HT 3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks